 Verve Therapeutics Inc. shares soared 68 in their trading debut Thursday, after the Massachusetts-based biotechnology companys upsized initial public offering priced above the expected range to value the company at about 832.6 million. Verve, which focuses on genetic medicines for cardiovascular disease, sold 14.04 million shares in the IPO, which priced at 19 a share, to raise 266.7 million. 